These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2243350)

  • 1. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II.
    Kirby KC; Stitzer ML; Heishman SJ
    J Pharmacol Exp Ther; 1990 Nov; 255(2):730-7. PubMed ID: 2243350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute physical dependence: time course and relation to human plasma morphine concentrations.
    June HL; Stitzer ML; Cone E
    Clin Pharmacol Ther; 1995 Mar; 57(3):270-80. PubMed ID: 7697945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    Pharmacol Biochem Behav; 1990 Jun; 36(2):393-9. PubMed ID: 2356213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute physical dependence in man: effects of naloxone after brief morphine exposure.
    Bickel WK; Stitzer ML; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):126-32. PubMed ID: 3335995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mianserin attenuates naloxone-precipitated withdrawal signs in rats acutely or chronically dependent upon morphine.
    Neal BS; Sparber SB
    J Pharmacol Exp Ther; 1986 Jan; 236(1):157-65. PubMed ID: 3001281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
    Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
    J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute opioid physical dependence in humans: maximum morphine-naloxone interval.
    Kirby KC; Stitzer ML; Heishman SJ
    NIDA Res Monogr; 1989; 95():393-4. PubMed ID: 2641007
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opiate withdrawal-induced hyposensitivity to naloxone's effects on serum luteinizing hormone in the male rat.
    Cicero TJ; Aleem A; Meyer ER; Schmoeker PF; Miller BT
    J Pharmacol Exp Ther; 1986 Sep; 238(3):1063-70. PubMed ID: 3528453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute opioid physical dependence in humans: effects of varying the morphine-morphine interval.
    Kirby KC; Stitzer ML
    NIDA Res Monogr; 1990; 105():449-50. PubMed ID: 1876071
    [No Abstract]   [Full Text] [Related]  

  • 17. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice.
    Miyamoto Y; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1141-5. PubMed ID: 8383738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat.
    Lee PH; McNutt RW; Chang KJ
    J Pharmacol Exp Ther; 1993 Nov; 267(2):883-7. PubMed ID: 8246163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of plasma catecholamines in eliciting cardiovascular changes seen during naloxone-precipitated withdrawal in conscious, unrestrained morphine-dependent rats.
    Chang AP; Dixon WR
    J Pharmacol Exp Ther; 1990 Sep; 254(3):857-63. PubMed ID: 2395117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.